WS
WST
Year ended Dec 31, 2024 · FY2025 10-K

West Pharmaceutical Services (WST) 10-K Summary — Year Ended Dec 31, 2024

West Pharmaceutical Services reported stable revenue and solid profitability for the fiscal year. The company maintained strong operating cash flow despite a slight revenue decline.

Key takeaway

Year ended Dec 31, 2024 · FY2025 10-K

West Pharmaceutical Services reported stable revenue and solid profitability for the fiscal year. The company maintained strong operating cash flow despite a slight revenue decline.

Financial snapshot

Selected annual figures reported with the filing, shown separately from the narrative summary.

Annual revenue

$2.9B

Revenue reported for the fiscal year.

Operating income

$569.9M

Income from operations reported for the year.

Net income

$492.7M

Net income reported for the year.

Operating cash flow

$653.4M

Cash generated by operating activities.

Annual revenue trend

Reported annual revenue and its change from the preceding fiscal year.

Period endedRevenueYear-over-year change
Dec 31, 2021$2.8Bn/a
Dec 31, 2022$2.9B+2.0%
Dec 31, 2023$2.9B+2.2%
Dec 31, 2024$2.9B-1.9%

Business overview

The company provides components and systems for pharmaceutical packaging and delivery. Its offerings include containment and delivery solutions for injectable drugs. Operations are focused on serving global pharmaceutical and biotech customers.

Financial performance

Revenue remained near prior year levels, while operating income and net income were positive and substantial. Operating cash flow was robust, exceeding net income, indicating efficient cash generation.

Material risks

The filing outlines risks common to the pharmaceutical supply industry, including regulatory changes and customer concentration. Supply chain disruptions and competition are also noted as potential concerns.

Liquidity and capital

The company maintained a strong liquidity position with operating cash flow supporting capital allocation priorities.

What to watch

Monitor revenue trends in the next filing for signs of recovery or further contraction.